Aerska, a biotechnology company developing brain shuttle technology to deliver RNA interference (RNAi) therapeutics to the brain, has closed a $39 million Series A funding round. This latest investment brings the company’s total funding to $60 million. The round was led by EQT Dementia Fund and age1, with additional support from Iaso Ventures and existing investors.
As part of the financing, Arno de Wilde, managing director at EQT; Philip Scheltens, partner and head of the dementia fund at EQT; and Alex Colville, general partner at age1, will join Aerska’s board of directors.
**Why this matters**
Delivering RNAi therapeutics across the blood-brain barrier remains a significant challenge in treating neurological diseases. Aerska’s brain shuttle technology aims to overcome this barrier, potentially enabling more effective treatments for brain disorders. The new funding will support the company’s research and development efforts in this area.
Source: NewsData